Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide(CC-92480), Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM): Successor-1 Clinical Trial ( IRB ) #: W25-296-1 Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide(CC-92480), Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM): Successor-1 Principal Investigator: Dr. Swarup Kumar Description: The purpose of the study is to find out how well an investigational drug combination called MeziVd (mezigdomide (Mezi) in combination with bortezomib[V] and dexamethasone [d])), works to treat multiple myeloma, when compared with PVd (pomalidomide [P] in combination with bortezomib [V] and dexamethasone [d]). PVd is a recommended treatment regimen for multiple myeloma in many countries. Classification:   Cancer - General Eligibility Criteria: Check with study contact How to Contact: Kristen Grandonico. Telephone: 860-679-6580. Email: grandonico@uchc.edu Enrollment Status/Comments: Enrolling/recruiting.